Yaktapour, Niuscha <br/><br/>
BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.  [electronic resource] 

 -  The Journal of clinical investigation  Nov 2014 
 - 5074-84 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1558-8238 
<br/><br/><label>Standard No.: </label>10.1172/JCI76539  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--adverse effects<br/>Cell Line, Tumor<br/>Cell Proliferation<br/>Cell Survival--drug effects<br/>Extracellular Signal-Regulated MAP Kinases--metabolism<br/>Humans<br/>Indoles--adverse effects<br/>Intracellular Signaling Peptides and Proteins--antagonists & inhibitors<br/>Leukemia, Lymphocytic, Chronic, B-Cell--chemically induced<br/>MAP Kinase Signaling System<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Mutation, Missense<br/>Phosphorylation<br/>Protein Processing, Post-Translational<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Proto-Oncogene Proteins B-raf--antagonists & inhibitors<br/>Radionuclide Imaging<br/>Skin Neoplasms--drug therapy<br/>Sulfonamides--adverse effects<br/>Syk Kinase<br/>Treatment Outcome<br/>Vemurafenib